BACKGROUND: Patients with diffuse intrinsic pontine glioma (DIPG) have a very poor prognosis. Only radiotherapy (XRT) has proven to be effective in delaying the disease progression. Several chemotherapy schedules have been applied so far, but none demonstrated significant improvements in progression and survival. METHODS: We retrospectively analyzed the clinical data of children diagnosed with DIPG at our center (Pediatric Hospital "Regina Margherita," Turin, Italy) between 1999 and 2013. Progression-free survival (PFS) and overall survival (OS) were used to describe the outcomes. RESULTS: Twenty-four children were included in our report. Patients diagnosed before March 2003 (n = 12) were treated with XRT and vincristine (VCR); the remaining 12 patients received XRT and temozolomide (TMZ). Progression-free survival was 18.8 % at 1 year (SE = 7.6 %), while overall survival was 44.1 % at 1 year (SE = 9.9 %). Median PFS was 8.1 months, whereas median OS was 11.2 months. No statistically significant difference in PFS or OS was evidenced between the two treatment groups. CONCLUSION: Radiotherapy followed by VCR or TMZ allows obtaining results that are in line with previous reports, with no advantages over other similar treatment schedules. DIPGs are challenging tumors with a dismal outcome. Further research and newer therapies are urgently needed in order to achieve improvements in survival.
BACKGROUND:Patients with diffuse intrinsic pontine glioma (DIPG) have a very poor prognosis. Only radiotherapy (XRT) has proven to be effective in delaying the disease progression. Several chemotherapy schedules have been applied so far, but none demonstrated significant improvements in progression and survival. METHODS: We retrospectively analyzed the clinical data of children diagnosed with DIPG at our center (Pediatric Hospital "Regina Margherita," Turin, Italy) between 1999 and 2013. Progression-free survival (PFS) and overall survival (OS) were used to describe the outcomes. RESULTS: Twenty-four children were included in our report. Patients diagnosed before March 2003 (n = 12) were treated with XRT and vincristine (VCR); the remaining 12 patients received XRT and temozolomide (TMZ). Progression-free survival was 18.8 % at 1 year (SE = 7.6 %), while overall survival was 44.1 % at 1 year (SE = 9.9 %). Median PFS was 8.1 months, whereas median OS was 11.2 months. No statistically significant difference in PFS or OS was evidenced between the two treatment groups. CONCLUSION: Radiotherapy followed by VCR or TMZ allows obtaining results that are in line with previous reports, with no advantages over other similar treatment schedules. DIPGs are challenging tumors with a dismal outcome. Further research and newer therapies are urgently needed in order to achieve improvements in survival.
Authors: David N Korones; Paul G Fisher; Cynthia Kretschmar; Tianni Zhou; Zhengjia Chen; James Kepner; Carolyn Freeman Journal: Pediatr Blood Cancer Date: 2008-02 Impact factor: 3.167
Authors: Kenneth J Cohen; Richard L Heideman; Tianni Zhou; Emiko J Holmes; Robert S Lavey; Eric Bouffet; Ian F Pollack Journal: Neuro Oncol Date: 2011-02-22 Impact factor: 12.300
Authors: Hiral P Fontanilla; Chelsea C Pinnix; Leena M Ketonen; Shiao Y Woo; Tribhawan S Vats; Michael E Rytting; Johannes E Wolff; Anita Mahajan Journal: Am J Clin Oncol Date: 2012-02 Impact factor: 2.339
Authors: R D Jenkin; C Boesel; I Ertel; A Evans; R Hittle; J Ortega; R Sposto; W Wara; C Wilson; J Anderson Journal: J Neurosurg Date: 1987-02 Impact factor: 5.115
Authors: John Glod; Gilbert J Rahme; Harpreet Kaur; Eric H Raabe; Eugene I Hwang; Mark A Israel Journal: J Pediatr Hematol Oncol Date: 2016-05 Impact factor: 1.289
Authors: Tabitha Cooney; Adam Lane; Ute Bartels; Eric Bouffet; Stewart Goldman; Sarah E S Leary; Nicholas K Foreman; Roger J Packer; Alberto Broniscer; Jane E Minturn; Chie-Schin Shih; Murali Chintagumpala; Tim Hassall; Nicholas G Gottardo; Hetal Dholaria; Lindsey Hoffman; Brooklyn Chaney; Joshua Baugh; Renee Doughman; James L Leach; Blaise V Jones; Maryam Fouladi; Katherine E Warren; Michelle Monje Journal: Neuro Oncol Date: 2017-09-01 Impact factor: 12.300
Authors: Paul Steinbok; Chittur Viswanathan Gopalakrishnan; Alexander R Hengel; Aleksander M Vitali; Ken Poskitt; Cynthia Hawkins; James Drake; Maria Lamberti-Pasculli; Olufemi Ajani; Walter Hader; Vivek Mehta; P Daniel McNeely; Patrick J McDonald; Adrianna Ranger; Michael Vassilyadi; Jeff Atkinson; Scott Ryall; David D Eisenstat; Juliette Hukin Journal: Childs Nerv Syst Date: 2015-11-23 Impact factor: 1.475
Authors: Matthew Gallitto; Stanislav Lazarev; Isaac Wasserman; James M Stafford; Suzanne L Wolden; Stephanie A Terezakis; Ranjit S Bindra; Richard L Bakst Journal: Adv Radiat Oncol Date: 2019-03-30